{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:01:12Z","timestamp":1758808872280,"version":"3.35.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11064-024-04275-w","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:20:58Z","timestamp":1731586858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Acute Haloperidol Treatment on Dopaminergic Markers, GAD67, and A2A Receptors in Rats with High and Low VCMs"],"prefix":"10.1007","volume":"50","author":[{"given":"Getulio Nicola","family":"Bressan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talita","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Eduarda Brandli","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Rosa Chitolina","family":"Schetinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahisa","family":"Scussel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Andrez","family":"Machado-de-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9ssica da Silva","family":"Abel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roselei","family":"Fachinetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"4275_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1192\/BJP.BP.108.050088","volume":"193","author":"DD Miller","year":"2008","unstructured":"Miller DD, Caroff SN, Davis SM et al (2008) Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 193:279\u2013288. https:\/\/doi.org\/10.1192\/BJP.BP.108.050088","journal-title":"Br J Psychiatry"},{"key":"4275_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/B978-0-444-52014-2.00043-4","volume":"100","author":"D Tarsy","year":"2011","unstructured":"Tarsy D, Lungu C, Baldessarini RJ (2011) Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol 100:601\u2013616. https:\/\/doi.org\/10.1016\/B978-0-444-52014-2.00043-4","journal-title":"Handb Clin Neurol"},{"key":"4275_CR3","doi-asserted-by":"publisher","first-page":"6536","DOI":"10.4088\/JCP.TV17016AH4C","volume":"78","author":"CU Correll","year":"2017","unstructured":"Correll CU, Kane JM, Citrome LL (2017) Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and advances in treatment. J Clin Psychiatry 78:6536. https:\/\/doi.org\/10.4088\/JCP.TV17016AH4C","journal-title":"J Clin Psychiatry"},{"key":"4275_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1001\/ARCHPSYC.1982.04290040069010","volume":"39","author":"JM Kane","year":"1982","unstructured":"Kane JM, Smith JM (1982) Tardive Dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 39:473\u2013481. https:\/\/doi.org\/10.1001\/ARCHPSYC.1982.04290040069010","journal-title":"Arch Gen Psychiatry"},{"key":"4275_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jns.2018.02.007","volume":"389","author":"A D\u2019Abreu","year":"2018","unstructured":"D\u2019Abreu A, Akbar U, Friedman JH (2018) Tardive dyskinesia: Epidemiology. J Neurol Sci 389:17\u201320. https:\/\/doi.org\/10.1016\/j.jns.2018.02.007","journal-title":"J Neurol Sci"},{"key":"4275_CR6","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.4088\/JCP.16r10832","volume":"78","author":"M Carbon","year":"2017","unstructured":"Carbon M, Hsieh C-H, Kane JM, Correll CU (2017) Tardive Dyskinesia Prevalence in the period of second-generation antipsychotic use. J Clin Psychiatry 78:e264\u2013e278. https:\/\/doi.org\/10.4088\/JCP.16r10832","journal-title":"J Clin Psychiatry"},{"key":"4275_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/MDS.25107","volume":"27","author":"JT Teo","year":"2012","unstructured":"Teo JT, Edwards MJ, Bhatia K (2012) Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord 27:1205\u20131215. https:\/\/doi.org\/10.1002\/MDS.25107","journal-title":"Mov Disord"},{"key":"4275_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/978-3-642-70140-5_16","volume":"2","author":"CA Tamminga","year":"1985","unstructured":"Tamminga CA, Thaker GK, Chase TN (1985) GABA dysfunction in the pathophysiology of Tardive Dyskinesia. Psychopharmacol Suppl 2:122\u2013127. https:\/\/doi.org\/10.1007\/978-3-642-70140-5_16","journal-title":"Psychopharmacol Suppl"},{"key":"4275_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.pnpbp.2012.10.018","volume":"46","author":"CH Cho","year":"2013","unstructured":"Cho CH, Lee HJ (2013) Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Prog Neuropsychopharmacol Biol Psychiatry 46:207\u2013213. https:\/\/doi.org\/10.1016\/j.pnpbp.2012.10.018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"4275_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1176\/APPI.AJP.158.3.360\/ASSET\/IMAGES\/LARGE\/Q93F2.JPEG","volume":"158","author":"S Kapur","year":"2001","unstructured":"Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360\u2013369. https:\/\/doi.org\/10.1176\/APPI.AJP.158.3.360\/ASSET\/IMAGES\/LARGE\/Q93F2.JPEG","journal-title":"Am J Psychiatry"},{"key":"4275_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000477313","volume":"86","author":"G Chouinard","year":"2017","unstructured":"Chouinard G, Samaha AN, Chouinard VA et al (2017) Antipsychotic-Induced dopamine supersensitivity psychosis: Pharmacology, Criteria, and Therapy. Psychother Psychosom 86:189\u2013219. https:\/\/doi.org\/10.1159\/000477313","journal-title":"Psychother Psychosom"},{"key":"4275_CR12","doi-asserted-by":"publisher","first-page":"107630","DOI":"10.1016\/J.NEUROPHARM.2019.05.007","volume":"163","author":"A Servonnet","year":"2020","unstructured":"Servonnet A, Samaha AN (2020) Antipsychotic-evoked dopamine supersensitivity. Neuropharmacology 163:107630. https:\/\/doi.org\/10.1016\/J.NEUROPHARM.2019.05.007","journal-title":"Neuropharmacology"},{"key":"4275_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/BF00427260","volume":"81","author":"LM Gunne","year":"1983","unstructured":"Gunne LM, H\u00e4ggstr\u00f6m JE (1983) Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia. Psychopharmacology 81:191\u2013194. https:\/\/doi.org\/10.1007\/BF00427260","journal-title":"Psychopharmacology"},{"key":"4275_CR14","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S0166-2236(84)80254-4","volume":"7","author":"C Fibiger","year":"1984","unstructured":"Fibiger C, Lloyd HG K (1984) Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci 7:462\u2013464. https:\/\/doi.org\/10.1016\/S0166-2236(84)80254-4","journal-title":"Trends Neurosci"},{"key":"4275_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41582-020-0359-x","volume":"16","author":"F Graus","year":"2020","unstructured":"Graus F, Saiz A, Dalmau J (2020) GAD antibodies in neurological disorders \u2014 insights and challenges. Nat Rev Neurol 16:353\u2013365. https:\/\/doi.org\/10.1038\/s41582-020-0359-x","journal-title":"Nat Rev Neurol"},{"key":"4275_CR16","doi-asserted-by":"publisher","unstructured":"Schmidt MJ, Mirnics K (2014) Neurodevelopment, GABA System Dysfunction, and Schizophrenia. Neuropsychopharmacology 2015 40:1 40:190\u2013206. https:\/\/doi.org\/10.1038\/npp.2014.95","DOI":"10.1038\/npp.2014.95"},{"key":"4275_CR17","doi-asserted-by":"publisher","first-page":"1161608","DOI":"10.3389\/FNCEL.2023.1161608\/BIBTEX","volume":"17","author":"K Fujihara","year":"2023","unstructured":"Fujihara K (2023) Beyond the \u03b3-aminobutyric acid hypothesis of schizophrenia. Front Cell Neurosci 17:1161608. https:\/\/doi.org\/10.3389\/FNCEL.2023.1161608\/BIBTEX","journal-title":"Front Cell Neurosci"},{"key":"4275_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.pneurobio.2007.05.001","volume":"83","author":"SN Schiffmann","year":"2007","unstructured":"Schiffmann SN, Fisone G, Moresco R et al (2007) Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 83:277\u2013292. https:\/\/doi.org\/10.1016\/j.pneurobio.2007.05.001","journal-title":"Prog Neurobiol"},{"key":"4275_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/S43440-020-00069-3\/FIGURES\/4","volume":"72","author":"W Romero-Fernandez","year":"2020","unstructured":"Romero-Fernandez W, Zhou Z, Beggiato S et al (2020) Acute cocaine treatment enhances the antagonistic allosteric adenosine A2A-dopamine D2 receptor\u2013receptor interactions in rat dorsal striatum without increasing significantly extracellular dopamine levels. Pharmacol Rep 72:332\u2013339. https:\/\/doi.org\/10.1007\/S43440-020-00069-3\/FIGURES\/4","journal-title":"Pharmacol Rep"},{"key":"4275_CR20","doi-asserted-by":"publisher","first-page":"E3609","DOI":"10.1073\/PNAS.1507704112\/SUPPL_FILE\/PNAS.201507704SI.PDF","volume":"112","author":"J Bonaventura","year":"2015","unstructured":"Bonaventura J, Navarro G, Casad\u00f3-Anguera V et al (2015) Allosteric interactions between agonists and antagonists within the adenosine A2A receptordopamine D2 receptor heterotetramer. Proc Natl Acad Sci U S A 112:E3609\u2013E3618. https:\/\/doi.org\/10.1073\/PNAS.1507704112\/SUPPL_FILE\/PNAS.201507704SI.PDF","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4275_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/J.PHYSBEH.2007.05.034","volume":"92","author":"K Fuxe","year":"2007","unstructured":"Fuxe K, Ferr\u00e9 S, Genedani S et al (2007) Adenosine receptor\u2013dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol Behav 92:210\u2013217. https:\/\/doi.org\/10.1016\/J.PHYSBEH.2007.05.034","journal-title":"Physiol Behav"},{"key":"4275_CR22","doi-asserted-by":"publisher","unstructured":"Negida A, Elfil M, Attia A et al (2016) Caffeine; the Forgotten potential for Parkinson\u2019s Disease. CNS Neurol Disord Drug Targets 16. https:\/\/doi.org\/10.2174\/1871527315666161107091149","DOI":"10.2174\/1871527315666161107091149"},{"key":"4275_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/J.PARKRELDIS.2016.08.005","volume":"32","author":"M Moccia","year":"2016","unstructured":"Moccia M, Erro R, Picillo M et al (2016) Caffeine consumption and the 4-year progression of de novo Parkinson\u2019s disease. Parkinsonism Relat Disord 32:116\u2013119. https:\/\/doi.org\/10.1016\/J.PARKRELDIS.2016.08.005","journal-title":"Parkinsonism Relat Disord"},{"key":"4275_CR24","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S0166-2236(97)01096-5","volume":"20","author":"S Ferr\u00e9","year":"1997","unstructured":"Ferr\u00e9 S, Fredholm BB, Morelli M et al (1997) Adenosine\u2013dopamine receptor\u2013receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20:482\u2013487. https:\/\/doi.org\/10.1016\/S0166-2236(97)01096-5","journal-title":"Trends Neurosci"},{"key":"4275_CR25","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/J.NEUROPHARM.2011.06.025","volume":"61","author":"M Orr\u00fa","year":"2011","unstructured":"Orr\u00fa M, Quiroz C, Guitart X, Ferr\u00e9 S (2011) Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum. Neuropharmacology 61:967\u2013974. https:\/\/doi.org\/10.1016\/J.NEUROPHARM.2011.06.025","journal-title":"Neuropharmacology"},{"key":"4275_CR26","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/J.PNPBP.2007.06.028","volume":"31","author":"R Fachinetto","year":"2007","unstructured":"Fachinetto R, Villarinho JG, Wagner C et al (2007) Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter. Prog Neuropsychopharmacol Biol Psychiatry 31:1478\u20131486. https:\/\/doi.org\/10.1016\/J.PNPBP.2007.06.028","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"4275_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pnpbp.2014.04.006","volume":"54","author":"J R\u00f6pke","year":"2014","unstructured":"R\u00f6pke J, Busanello A, Leal CQ et al (2014) Anandamide attenuates haloperidol-induced vacuous chewing movements in rats. Prog Neuropsychopharmacol Biol Psychiatry 54:195\u2013199. https:\/\/doi.org\/10.1016\/j.pnpbp.2014.04.006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"4275_CR28","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/S11064-016-1961-6\/FIGURES\/4","volume":"41","author":"LR Peroza","year":"2016","unstructured":"Peroza LR, Schaffer LF, De Freitas CM et al (2016) Alteration of cytokines levels in the striatum of rats: possible participation in Vacuous Chewing movements Induced by Antipsycotics. Neurochem Res 41:2481\u20132489. https:\/\/doi.org\/10.1007\/S11064-016-1961-6\/FIGURES\/4","journal-title":"Neurochem Res"},{"key":"4275_CR29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s00213-002-1259-z","volume":"165","author":"P Turrone","year":"2003","unstructured":"Turrone P, Remington G, Kapur S, Nobrega JN (2003) The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology 165:166\u2013171. https:\/\/doi.org\/10.1007\/s00213-002-1259-z","journal-title":"Psychopharmacology"},{"key":"4275_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/BF02245101","volume":"117","author":"MF Egan","year":"1995","unstructured":"Egan MF, Wyatt RJ, Hyde TM, Kleinman JE (1995) Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose. Psychopharmacology 117:74\u201381. https:\/\/doi.org\/10.1007\/BF02245101","journal-title":"Psychopharmacology"},{"key":"4275_CR31","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbr.2016.10.049","volume":"320","author":"M Kronbauer","year":"2017","unstructured":"Kronbauer M, Metz VG, Roversi K et al (2017) Influence of magnesium supplementation on movement side effects related to typical antipsychotic treatment in rats. Behav Brain Res 320:400\u2013411. https:\/\/doi.org\/10.1016\/j.bbr.2016.10.049","journal-title":"Behav Brain Res"},{"key":"4275_CR32","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0301-0082(99)00064-7","volume":"61","author":"OA Andreassen","year":"2000","unstructured":"Andreassen OA, J\u00f8rgensen HA (2000) Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats: implications for tardive dyskinesia? Prog Neurobiol 61:525\u2013541. https:\/\/doi.org\/10.1016\/S0301-0082(99)00064-7","journal-title":"Prog Neurobiol"},{"key":"4275_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0149-7634(02)00008-8","volume":"26","author":"P Turrone","year":"2002","unstructured":"Turrone P, Remington G, Nobrega JN (2002) The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D2 receptor occupancy? Neurosci Biobehav Rev 26:361\u2013380. https:\/\/doi.org\/10.1016\/S0149-7634(02)00008-8","journal-title":"Neurosci Biobehav Rev"},{"key":"4275_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s002130050095","volume":"127","author":"MF Egan","year":"1996","unstructured":"Egan MF, Hurd Y, Ferguson J et al (1996) Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology 127:337\u2013345. https:\/\/doi.org\/10.1007\/s002130050095","journal-title":"Psychopharmacology"},{"key":"4275_CR35","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00213-007-0831-y","volume":"194","author":"R Fachinetto","year":"2007","unstructured":"Fachinetto R, Villarinho JG, Wagner C et al (2007) Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats. Psychopharmacology 194:423\u2013432. https:\/\/doi.org\/10.1007\/s00213-007-0831-y","journal-title":"Psychopharmacology"},{"key":"4275_CR36","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/S11064-015-1811-Y\/FIGURES\/9","volume":"41","author":"LF Schaffer","year":"2016","unstructured":"Schaffer LF, de Freitas CM, Chiapinotto Ceretta AP et al (2016) Harpagophytum Procumbens Ethyl acetate fraction reduces Fluphenazine-Induced Vacuous chewing movements and oxidative stress in rat brain. Neurochem Res 41:1170\u20131184. https:\/\/doi.org\/10.1007\/S11064-015-1811-Y\/FIGURES\/9","journal-title":"Neurochem Res"},{"key":"4275_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/J.PBB.2012.01.007","volume":"101","author":"A Busanello","year":"2012","unstructured":"Busanello A, Peroza LR, Wagner C et al (2012) Resveratrol reduces vacuous chewing movements induced by acute treatment with fluphenazine. Pharmacol Biochem Behav 101:307\u2013310. https:\/\/doi.org\/10.1016\/J.PBB.2012.01.007","journal-title":"Pharmacol Biochem Behav"},{"key":"4275_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/S11064-017-2335-4","volume":"42","author":"A Busanello","year":"2017","unstructured":"Busanello A, Leal CQ, Peroza LR et al (2017) Resveratrol protects against Vacuous Chewing movements Induced by Chronic Treatment with Fluphenazine. Neurochemical Res 2017 42:11. https:\/\/doi.org\/10.1007\/S11064-017-2335-4","journal-title":"Neurochemical Res 2017"},{"key":"4275_CR39","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00213-015-4118-4","volume":"233","author":"CM de Freitas","year":"2016","unstructured":"de Freitas CM, Busanello A, Schaffer LF et al (2016) Behavioral and neurochemical effects induced by reserpine in mice. Psychopharmacology 233:457\u2013467. https:\/\/doi.org\/10.1007\/s00213-015-4118-4","journal-title":"Psychopharmacology"},{"key":"4275_CR40","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0024-3205(01)01178-X","volume":"69","author":"R Soto-Otero","year":"2001","unstructured":"Soto-Otero R, M\u00e9ndez-\u00c1lvarez E, Hermida-Ameijeiras \u00c1 et al (2001) Inhibition of brain monoamine oxidase activity by the generation of hydroxyl radicals potential implications in relation to oxidative stress. Life Sci 69:879\u2013889. https:\/\/doi.org\/10.1016\/S0024-3205(01)01178-X","journal-title":"Life Sci"},{"key":"4275_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0160-5402(85)90021-X","volume":"13","author":"A Morinan","year":"1985","unstructured":"Morinan A, Garratt HM (1985) An improved fluorimetric assay for brain monoamine oxidase. J Pharmacol Methods 13:213\u2013223. https:\/\/doi.org\/10.1016\/0160-5402(85)90021-X","journal-title":"J Pharmacol Methods"},{"key":"4275_CR42","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/J.JPBA.2014.05.039","volume":"98","author":"GE De Benedetto","year":"2014","unstructured":"De Benedetto GE, Fico D, Pennetta A et al (2014) A rapid and simple method for the determination of 3,4-dihydroxyphenylacetic acid, norepinephrine, dopamine, and serotonin in mouse brain homogenate by HPLC with fluorimetric detection. J Pharm Biomed Anal 98:266\u2013270. https:\/\/doi.org\/10.1016\/J.JPBA.2014.05.039","journal-title":"J Pharm Biomed Anal"},{"key":"4275_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin Phenol Reagent. J Biol Chem 193:265\u2013275. https:\/\/doi.org\/10.1016\/S0021-9258(19)52451-6","journal-title":"J Biol Chem"},{"key":"4275_CR44","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/J.AB.2010.02.036","volume":"401","author":"I Romero-Calvo","year":"2010","unstructured":"Romero-Calvo I, Oc\u00f3n B, Mart\u00ednez-Moya P et al (2010) Reversible Ponceau staining as a loading control alternative to actin in Western blots. Anal Biochem 401:318\u2013320. https:\/\/doi.org\/10.1016\/J.AB.2010.02.036","journal-title":"Anal Biochem"},{"issue":"12","key":"4275_CR45","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/S00210-020-01923-0","volume":"393","author":"JB Reinheimer","year":"2020","unstructured":"Reinheimer JB, Bressan GN, de Freitas CM et al (2020) Effects of CATECHIN on reserpine-induced vacuous chewing movements: behavioral and biochemical analysis. Naunyn-Schmiedeberg\u2019s Archives Pharmacol 2020 393(12):2439\u20132452. https:\/\/doi.org\/10.1007\/S00210-020-01923-0","journal-title":"Naunyn-Schmiedeberg\u2019s Archives Pharmacol 2020"},{"key":"4275_CR46","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.fct.2018.05.062","volume":"118","author":"CM de Freitas","year":"2018","unstructured":"de Freitas CM, Krum BN, Chiapinotto Ceretta AP et al (2018) Silymarin recovers 6-hydroxydopamine-induced motor deficits in mice. Food Chem Toxicol 118:549\u2013556. https:\/\/doi.org\/10.1016\/j.fct.2018.05.062","journal-title":"Food Chem Toxicol"},{"key":"4275_CR47","first-page":"24609","volume":"5","author":"SM Stahl","year":"2003","unstructured":"Stahl SM (2003) Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. Prim Care Companion CNS Disord 5:24609","journal-title":"Prim Care Companion CNS Disord"},{"key":"4275_CR48","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1111\/J.1460-9568.2004.03547.X","volume":"20","author":"K H\u00e5kansson","year":"2004","unstructured":"H\u00e5kansson K, Pozzi L, Usiello A et al (2004) Regulation of striatal tyrosine hydroxylase phosphorylation by acute and chronic haloperidol. Eur J Neurosci 20:1108\u20131112. https:\/\/doi.org\/10.1111\/J.1460-9568.2004.03547.X","journal-title":"Eur J Neurosci"},{"key":"4275_CR49","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1038\/s41380-018-0114-5","volume":"25","author":"D Amato","year":"2020","unstructured":"Amato D, Canneva F, Cumming P et al (2020) A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. Mol Psychiatry 25:2101\u20132118. https:\/\/doi.org\/10.1038\/s41380-018-0114-5","journal-title":"Mol Psychiatry"},{"key":"4275_CR50","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1146\/annurev.bi.40.070171.002341","volume":"40","author":"PB Molinoff","year":"1971","unstructured":"Molinoff PB, Axelrod J (1971) Biochemistry of catecholamines. Annu Rev Biochem 40:465\u2013500. https:\/\/doi.org\/10.1146\/annurev.bi.40.070171.002341","journal-title":"Annu Rev Biochem"},{"key":"4275_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.abb.2010.12.017","volume":"508","author":"SC Daubner","year":"2011","unstructured":"Daubner SC, Le T, Wang S (2011) Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 508:1\u201312. https:\/\/doi.org\/10.1016\/j.abb.2010.12.017","journal-title":"Arch Biochem Biophys"},{"key":"4275_CR52","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrn1883","volume":"7","author":"MBH Youdim","year":"2006","unstructured":"Youdim MBH, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295\u2013309. https:\/\/doi.org\/10.1038\/nrn1883","journal-title":"Nat Rev Neurosci"},{"key":"4275_CR53","doi-asserted-by":"publisher","first-page":"S287","DOI":"10.1038\/sj.bjp.0706464","volume":"147","author":"MBH Youdim","year":"2006","unstructured":"Youdim MBH, Bakhle YS (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson\u2019s disease and depressive illness. Br J Pharmacol 147:S287\u2013S296. https:\/\/doi.org\/10.1038\/sj.bjp.0706464","journal-title":"Br J Pharmacol"},{"key":"4275_CR54","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1523\/JNEUROSCI.2028-18.2018","volume":"39","author":"EF Lopes","year":"2019","unstructured":"Lopes EF, Roberts BM, Siddorn RE et al (2019) Inhibition of Nigrostriatal dopamine release by Striatal GABAA and GABAB receptors. J Neurosci 39:1058\u20131065. https:\/\/doi.org\/10.1523\/JNEUROSCI.2028-18.2018","journal-title":"J Neurosci"},{"key":"4275_CR55","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/J.BAGA.2016.02.001","volume":"6","author":"D Sulzer","year":"2016","unstructured":"Sulzer D, Cragg SJ, Rice ME (2016) Striatal dopamine neurotransmission: regulation of release and uptake. Basal Ganglia 6:123\u2013148. https:\/\/doi.org\/10.1016\/J.BAGA.2016.02.001","journal-title":"Basal Ganglia"},{"key":"4275_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0893-133X(01)00225-1","volume":"25","author":"FM Benes","year":"2001","unstructured":"Benes FM, Berretta S (2001) GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25:1\u201327. https:\/\/doi.org\/10.1016\/S0893-133X(01)00225-1","journal-title":"Neuropsychopharmacology"},{"key":"4275_CR57","doi-asserted-by":"publisher","unstructured":"Roberts BM, Doig NM, Brimblecombe KR et al (2020) GABA uptake transporters support dopamine release in dorsal striatum with maladaptive downregulation in a parkinsonism model. Nat Commun 11. https:\/\/doi.org\/10.1038\/S41467-020-18247-5","DOI":"10.1038\/S41467-020-18247-5"},{"key":"4275_CR58","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/J.EJPHAR.2006.09.010","volume":"552","author":"M Bishnoi","year":"2006","unstructured":"Bishnoi M, Chopra K, Kulkarni SK (2006) Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol 552:55\u201366. https:\/\/doi.org\/10.1016\/J.EJPHAR.2006.09.010","journal-title":"Eur J Pharmacol"},{"key":"4275_CR59","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/J.NEUROPHARM.2015.10.032","volume":"104","author":"U Kr\u00fcgel","year":"2016","unstructured":"Kr\u00fcgel U (2016) Purinergic receptors in psychiatric disorders. Neuropharmacology 104:212\u2013225. https:\/\/doi.org\/10.1016\/J.NEUROPHARM.2015.10.032","journal-title":"Neuropharmacology"},{"key":"4275_CR60","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1038\/s41598-017-02037-z","volume":"7","author":"PA de Oliveira","year":"2017","unstructured":"de Oliveira PA, Dalton JAR, L\u00f3pez-Cano M et al (2017) Angiotensin II type 1\/adenosine a 2A receptor oligomers: a novel target for tardive dyskinesia. Sci Rep 7:1857. https:\/\/doi.org\/10.1038\/s41598-017-02037-z","journal-title":"Sci Rep"},{"key":"4275_CR61","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.2174\/138161208784480108","volume":"14","author":"S Ferre","year":"2008","unstructured":"Ferre S, Quiroz C, Woods A et al (2008) An update on Adenosine A2A-Dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr Pharm Des 14:1468\u20131474. https:\/\/doi.org\/10.2174\/138161208784480108","journal-title":"Curr Pharm Des"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-024-04275-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-024-04275-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-024-04275-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T12:04:55Z","timestamp":1738411495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-024-04275-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["4275"],"URL":"https:\/\/doi.org\/10.1007\/s11064-024-04275-w","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"type":"print","value":"0364-3190"},{"type":"electronic","value":"1573-6903"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were performed following the guidelines of the National Council of Control of Animal Experimentation (CONCEA) and approved by the Institutional Committee of Care and Use of Animals of the Federal University of Santa Maria (UFSM), under number 6890220617\/2017.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"4"}}